se gb

Dilaforette AB announced today the appointment of Christina Herder as new CEO

STOCKHOLM, SWEDEN - January 22, 2014. Dilaforette AB, a company in Karolinska Development’s portfolio, announced today the appointment of Christina Herder as new CEO. Christina Herder, PhD, MBA, will bring over 20 years of experience in product development and business development from the pharmaceutical industry.

“We are delighted that Christina is joining Dilaforette. Her expertise and experience will help us take the company forward to successful outcomes in malaria and sickle cell disease. I look forward to working with her over the next years”, says Robin Wright, Chairman of Dilaforette.

Dilaforette is developing sevuparin, a proprietary polysaccharide-based drug, for treatment of hematological crisis in malaria as well as vaso-occlusive crisis in sickle cell disease.

“I am looking forward to lead Dilaforette and to develop sevuparin into new therapies for patients, with a large unmet medical need”, says Christina Herder.

Christina holds a PhD from Royal Institute of Technology in Stockholm, Sweden, and an MBA from Stockholm University. Christina Herder joins Dilaforette from Sobi, where she has been working within Corporate Development as well as previously heading up the Portfolio Management in R&D. She brings over 20 years of experience from pharmaceutical product development from Pharmacia, Medicarb, Biovitrum and Sobi. She has also been board member of Akinion Pharmaceuticals AB, for five years.

 

For further information, please contact:
Robin Wright, Chairman of Dilaforette AB
Phone: +44 7720 300 025
E-mail: robin.wright@karolinskadevelopment.com

 

TO THE EDITORS

About Dilaforette AB
Dilaforette is a Swedish drug development company developing sevuparin, a proprietary polysaccharide-based drug, for the treatment of severe malaria and vaso-occlusive crisis in Sickle Cell Disease.

In severe malaria, microvascular obstruction is caused by sequestration of parasitized red blood cells and adhesive forces between infected/uninfected red cells. This constitutes the central feature in the pathogenesis and is a direct cause of acidosis, coma and death.

Sickle cell disease is a genetic life shortening disorder where one main feature is the vaso-occlusive crisis caused by sickle cell shaped red blood cells that obstruct blood flow in capillaries, resulting in ischemia and severe pain. For more information, please visit www.dilaforette.se.

PDF.pngPDF version

2014-01-22